CPRX - Catalyst Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development11,369.94111,801.34210,117.774
Selling General and Administrative7,910.268,597.014,473.654
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-19,280.201-20,398.352-14,591.428
Income from Continuing Operations
Total Other Income/Expenses Net1,207.749165.394-917.633
Earnings Before Interest and Taxes-18,072.452-20,232.958-15,509.061
Interest Expense---
Income Before Tax-18,072.452-20,232.958-15,509.061
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-18,072.452-20,232.958-15,509.061
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-18,072.452-20,232.958-15,509.061
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-18,072.452-20,232.958-15,509.061